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The tumour microenvironment consists of a heteroge-
neous population of cancer-associated fibroblasts, leaky
vasculature, polarised and suppressed immune cells, and
hyperproliferative, transformed and invasive epithelial
cells. Capturing the complex phenotypic biology of the
tumour microenvironment in vitro is extremely challen-
ging as numerous components drive a malignant pheno-
type. Currently, cancer drug screening is limited by
lengthy clinical trials, rodent models unable to capture
human biology, and in vitro screening in monoculture
which ignores complex cell interactions. An in vitro
co-culture platform to mirror these cancer microenvir-
onments may permit phenotypic screening of multiple
cancer drugs to elucidate additive or synergistic effects
prior to clinical trials.
We have recently developed a panel of primary human
co-cultures, BioMAP® Oncology Systems, which mimic
the complexity of host-tumour stromal and vasculature
microenvironment. By using primary human fibroblast
or endothelial cells with stimulated peripheral blood
mononuclear cells (PBMCs) and the human epithelial ade-
nocarcinoma cell line HT-29, we are able to successfully
model a stromal or vascular tumour microenvironment.
These co-culture models allow us to generate a unique
profile of biological responses for drugs tested at multiple
concentrations. These biological responses are a function
of 41 cell-based and soluble protein readouts, measured by
immune-based methods, examining tumour-associated
immunomodulation, angiogenesis, matrix remodeling, and
cellular proliferation. Using paclitaxel as a model cancer
drug we found that it exhibited immunostimulatory char-
acteristics through upregulation of soluble GranzymeB,
TNFa, and IFNg. Upregulation of these readouts is found
in the clinic consistent with cancer cell death via T-cell-
dependent anti-tumour effects. We also screened typical
standards of care (SOC) for colon cancer, gemcitabine and
carboplatin, to determine their response profiles. Alterna-
tively, these systems can be used to screen potential cancer
drugs in combination or matrix format to assess therapeu-
tic strategies for synergistic or additive effects. Profiling of
cancer immunotherapeutics (e.g ipilimumab) in combina-
tion with current SOC provides insightful data for clini-
cians to understand immune-preserving and cancer-cell
killing activities.
Profiling of compounds across a panel of tumour micro-
environment co-cultures provides a powerful experimental
platform in primary human cell-based system that allows
researchers in early compound development to investigate
their drug’s potential therapeutic targets, and, at late-stage
development, accelerate a drug(s) track through clinical
testing. The ever increasing number of clinical trials using
multiple cancer drugs can be reduced by utilising a matrix
of drugs administered in our newly developed BioMAP®
oncology systems to determine which drugs in combina-
tion are of clinical efficacy.
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